Oregovomab clinical trials
Also written MAb-B43.13.
How each study uses oregovomab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
15 studies that test it; most in 1998 (2)
| Year | Studies |
|---|---|
| 1998 | 2 |
| 2000 | 1 |
| 2002 | 2 |
| 2004 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2017 | 2 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 12 · Other 3
CanariaBio Inc. (5) · Unither Pharmaceuticals (4) · National Cancer Centre, Singapore (2) · AltaRex (2) · University of Nebraska (1) · Quest PharmaTech Inc. (1)
Often tested with
Tested in the same studies.
Bevacizumab (1) · Paclitaxel (1) · Carboplatin (1) · Nelfinavir (1) · Poly ICLC (1) · Antineoplastic Agents (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3, 1 in phase 3
Studies that test oregovomab, phase 3 first.
- Dec 2026Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking SurgeryPhase 3 · CanariaBio Inc.
- Dec 2026A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.Phase 2 · CanariaBio Inc.
- May 2027Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian CancerPhase 2 · CanariaBio Inc.
Studies
Open first, then newest update. How each study uses oregovomab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 15
- Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian CancerActive, not recruitingPhase 2CanariaBio Inc.NCT05605535Written as Oregovomab
- Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian CancerActive, not recruitingPhase 1/2CanariaBio Inc.NCT04938583Written as Oregovomab
- A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.Active, not recruitingPhase 2CanariaBio Inc.NCT05335993Written as Oregovomab
- Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking SurgeryActive, not recruitingPhase 3CanariaBio Inc.NCT04498117Written as Oregovomab
- Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic CancerCompletedPhase 2University of NebraskaNCT01959672Written as Oregovomab
- Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal OriginTerminatedPhase 1/2National Cancer Centre, SingaporeNCT03100006Written as Oregovomab
- Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal OriginStatus unknownPhase 1/2National Cancer Centre, SingaporeNCT04620954Written as Oregovomab
- The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian CancerTerminatedPhase 1CanariaBio Inc.NCT03162562Written as Oregovomab
- A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian CancerCompletedPhase 2Quest PharmaTech Inc.NCT01616303Written as oregovomab
- Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and ChemotherapyStatus unknownPhase 2AltaRexNCT00003634Written as oregovomab
- Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal CancerStatus unknownPhase 2AltaRexNCT00004064Written as oregovomab
- Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian CarcinomaTerminatedPhase 2Unither PharmaceuticalsNCT00034372Written as oregovomab
- A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial CarcinomaTerminatedPhase 1/2Unither PharmaceuticalsNCT00034138Written as oregovomab
- Clinical Trial for Ovarian Cancer (OvaRex®)TerminatedPhase 3Unither PharmaceuticalsNCT00050375Written as oregovomab
- Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer TreatmentTerminatedPhase 2Unither PharmaceuticalsNCT00086632Written as oregovomab
Given beside what is tested · 1 — oregovomab is usual care or a partner of the new treatment
Codes
What other systems call oregovomab · ClinicalTrials.gg INT004006
- MeSH (NLM) C107428oregovomabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) HX101E7L6SOREGOVOMABConfirmed FDA, NLM, Wikidata
- Wikidata Q7101491OregovomabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1784OregovomabOne source FDA
- DrugBank DB04964One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C107428 | oregovomab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | HX101E7L6S | OREGOVOMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7101491 | Oregovomab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1784 | Oregovomab | One source FDA |
| DrugBank | DB04964 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.